AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX)
10.405 USD
+0.005 0.048%Sponsored Reports
Loading...
| Previous Close (in USD) | 10.4 |
|---|---|
| Change | +0.005 0.048% |
| 52 W H/L (in USD) | 8.880/4.030 |
| EBITDA (in USD) | -31.941M |
| PE Ratio | -- |
| Volume | 742767 |
| Diluted Eps TTM | -0.61 |
| Total Assets (in USD) | 516.96M |
|---|---|
| Total Liabilities (in USD) | 972.488M |
| Revenue TTM (in USD) | 412.579M |
| Cash (in USD) | 112.447M |
| Market Cap (in USD) | 1,601.138 M |
| Revenue Per Share TTM | 2.010 |
| Gross Profit TTM (in USD) | 10.936M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Employees: 536
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Jon P. Stonehouse | CEO, Pres & Exec. Director | 1961 |
| 2. | Mr. Anthony J. Doyle | Sr. VP & CFO | 1980 |
| 3. | Dr. William P. Sheridan MBBS | Chief Devel. Officer | 1955 |
| 4. | Dr. Yarlagadda S. Babu | Chief Discovery Officer | 1953 |
| 5. | Dr. Helen M. Thackray FAAP, M.D. | Chief R&D Officer | 1968 |
| 6. | Mr. Michael L. Jones | Exec. Director of Fin. & Principal Accounting Officer | 1970 |
| 7. | Ms. Alane P. Barnes | Sr. VP, Chief Legal Officer & Corp. Sec. | 1966 |
| 8. | Mr. John D. Bluth | Chief Communications Officer | 1973 |
| 9. | Ms. Stephanie Angelini | Chief People Officer | NA |
| 10. | Dr. Elliott T. Berger | Sr. VP of Regulatory Affairs | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.560 0.691% | 81.41 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.410 0.506% | 80 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-1.290 0.280% | 455.39 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+2.820 0.540% | 518.25 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -244.384M | -181.809M | -182.814M | -108.897M | -101.252M |
| Minority Interest | - | - | - | - | - |
| Net Income | -247.117M | -184.062M | -196.567M | -120.065M | -101.252M |
| Selling General Administrative | 159.371M | 118.818M | 67.929M | 37.121M | 29.514M |
| Gross Profit | 264.233M | 149.906M | 16.136M | 44.734M | 20.182M |
| Reconciled Depreciation | 1.437M | 0.777M | 0.748M | 0.724M | 0.77M |
| Ebit | -148.435M | -177.72M | -174.757M | -99.455M | -92.738M |
| Ebitda | -143.308M | -177.658M | -165.337M | -97.522M | -91.968M |
| Depreciation And Amortization | 5.127M | 0.062M | 9.42M | 1.933M | 0.77M |
| Operating Income | -148.435M | -177.72M | -174.757M | -99.455M | -94.22M |
| Other Operating Expenses | 419.262M | 334.89M | 192.569M | 148.29M | 114.873M |
| Interest Expense | 99.092M | 59.294M | 14.501M | 11.892M | 9.176M |
| Tax Provision | 2.733M | 2.253M | - | - | - |
| Interest Income | 5.127M | 0.062M | 9.42M | 1.933M | 2.252M |
| Net Interest Income | -93.965M | -59.232M | -5.081M | -9.959M | -6.924M |
| Income Tax Expense | 2.733M | 2.253M | 13.753M | 11.168M | 2.144M |
| Total Revenue | 270.827M | 157.17M | 17.812M | 48.835M | 20.653M |
| Total Operating Expenses | 412.668M | 327.626M | 190.893M | 144.189M | 114.402M |
| Cost Of Revenue | 6.594M | 7.264M | 1.676M | 4.101M | 0.471M |
| Total Other Income Expense Net | -95.949M | -4.089M | -8.057M | -9.442M | -0.108M |
| Net Income From Continuing Ops | -247.117M | -184.062M | -192.234M | -108.897M | -101.252M |
| Net Income Applicable To Common Shares | -247.116M | -184.062M | -182.814M | -108.897M | -101.252M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 516.96M | 550M | 588.151M | 334.715M | 175.282M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 19.542M | 12.586M | 9.986M | 5.528M | 4.422M |
| Total Liab | 972.488M | 844.597M | 695.137M | 353.977M | 137.03M |
| Total Stockholder Equity | -455.528M | -1454.621M | -1207.504M | -1023.442M | -840.628M |
| Other Current Liab | 102.882M | 87.565M | 72.67M | 55.612M | 36.269M |
| Common Stock | 2.058M | 1.879M | 1.843M | 1.769M | 1.541M |
| Capital Stock | 2.058M | 1.879M | 1.843M | 1.769M | 1.541M |
| Retained Earnings | -1681.159M | -1454.621M | -1207.504M | -1023.442M | -840.628M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 550M | 588.15M | - | - |
| Cash | 112.447M | 304.767M | 504.389M | 272.127M | 114.172M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 149.988M | 105.514M | 103.718M | 105.654M | 92.335M |
| Current Deferred Revenue | - | 1.224M | 1.421M | 0.15M | 2.12M |
| Net Debt | 736.266M | 436.685M | 88.849M | -147.41M | -29.519M |
| Short Term Debt | 26.213M | 2.369M | 1.819M | 31.179M | 39.958M |
| Short Long Term Debt | - | - | - | 30M | 38.581M |
| Short Long Term Debt Total | 848.713M | 741.452M | 593.238M | 124.717M | 84.653M |
| Other Stockholder Equity | 1222.236M | -1.905M | -2.02M | -1.772M | -1.58M |
| Property Plant Equipment | - | 15.423M | 15.186M | 7.113M | 7.347M |
| Total Current Assets | 495.966M | 516.5M | 566.136M | 323.8M | 164.345M |
| Long Term Investments | 0M | 18.077M | 6.829M | - | 0M |
| Short Term Investments | 278.344M | 119.543M | 3.212M | 28.239M | 22.054M |
| Net Receivables | 56.95M | 50.599M | 29.413M | 8.646M | 22.146M |
| Long Term Debt | 811.265M | 733.279M | 585.457M | 119.735M | 41.289M |
| Inventory | 28.683M | 27.533M | 15.791M | 7.039M | 1.551M |
| Accounts Payable | 20.893M | 14.356M | 27.808M | 18.713M | 13.988M |
| Accumulated Other Comprehensive Income | 1.337M | 0.026M | 0.177M | 0.003M | 0.039M |
| Non Currrent Assets Other | 12.026M | 6.806M | 6.472M | 3.802M | 3.59M |
| Non Current Assets Total | 20.994M | 33.5M | 22.015M | 10.915M | 10.937M |
| Capital Lease Obligations | 13.883M | 8.173M | 7.781M | 124.717M | 4.783M |
| Long Term Debt Total | - | - | 136.082M | 119.735M | 41.289M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -128.238M | 18.189M | -6.343M | 78.277M | 5.134M |
| Total Cashflows From Investing Activities | -128.238M | 15.804M | -6.856M | 77.934M | 4.768M |
| Total Cash From Financing Activities | 88.027M | 359.668M | 302.697M | 99.098M | 62.504M |
| Net Income | -247.116M | -184.062M | -182.814M | -108.897M | -101.252M |
| Change In Cash | -201.495M | 233.386M | 158.625M | 87.448M | -25.293M |
| Begin Period Cash Flow | 507.734M | 274.348M | 115.723M | 28.275M | 53.568M |
| End Period Cash Flow | 306.239M | 507.734M | 274.348M | 115.723M | 28.275M |
| Total Cash From Operating Activities | -161.85M | -142.157M | -137.216M | -89.584M | -92.565M |
| Depreciation | 1.437M | 0.777M | 0.748M | 0.724M | 0.77M |
| Other Cashflows From Investing Activities | - | - | 0.001M | 78.277M | 5.134M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -12.423M | -8.767M | -7.039M | 1.649M | -1.649M |
| Sale Purchase Of Stock | - | 65.794M | 110.542M | 79.621M | 56.252M |
| Other Cashflows From Financing Activities | 73.072M | 309.668M | 261.838M | 40.598M | 13.129M |
| Capital Expenditures | 1.351M | 2.385M | 0.514M | 0.343M | 0.366M |
| Change In Working Capital | -58.945M | 8.124M | 26.875M | -0.872M | -3.53M |
| Other Non Cash Items | 98.073M | 54.204M | 2.428M | 1.278M | 0.885M |
| Free Cash Flow | -163.201M | -144.542M | -137.73M | -89.927M | -92.931M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 7 months ago | 6517838 |
| 2. | iShares Russell 2000 ETF | 6 months ago | 5774825 |
| 3. | SPDR® S&P Biotech ETF | 6 months ago | 3993167 |
| 4. | Vanguard Institutional Extnd Mkt Idx Tr | 7 months ago | 3135422 |
| 5. | Vanguard Small Cap Index | 7 months ago | 2598180 |
| 6. | CREF Stock R1 | 9 months ago | 2294760 |
| 7. | Fidelity Small Cap Index | 8 months ago | 2096285 |
| 8. | iShares Russell 2000 Growth ETF | 6 months ago | 1863888 |
| 9. | Fidelity Select Biotechnology | 7 months ago | 1593581 |
| 10. | Vanguard Strategic Equity Inv | 8 months ago | 1517487 |
| 11. | Vanguard Small Cap Growth Index Inv | 7 months ago | 1428808 |
| 12. | Nuveen Quant Small Cap Equity R6 | 8 months ago | 1419080 |
| 13. | Vanguard Explorer Inv | 8 months ago | 1367293 |
| 14. | iShares Biotechnology ETF | 6 months ago | 1334287 |
| 15. | State St Russell Sm/Mid Cp® Indx NL Cl C | 7 months ago | 1288400 |
| 16. | BlackRock Advantage Small Cap Core Instl | 7 months ago | 1146899 |
| 17. | Fidelity Extended Market Index | 7 months ago | 1126994 |
| 18. | Schwab US Small-Cap ETF™ | 6 months ago | 1007551 |
| 19. | Vanguard Russell 2000 ETF | 7 months ago | 941866 |
| 20. | Invesco Biotechnology & Genome ETF | 6 months ago | 885927 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Two Sigma Advisers, LLC | 8 months ago | 2181012 |
| 2. | Rice Hall James & Associates, LLC | 8 months ago | 2163743 |
| 3. | FMR Inc | 8 months ago | 1988389 |
| 4. | Charles Schwab Investment Management Inc | 8 months ago | 1887994 |
| 5. | Vanguard Group Inc | 8 months ago | 20306596 |
| 6. | BlackRock Inc | 11 months ago | 19956255 |
| 7. | venBio Select Advisor LLC | 8 months ago | 11865000 |
| 8. | Kynam Capital Management, LP | 8 months ago | 9085368 |
| 9. | State Street Corp | 8 months ago | 8849588 |
| 10. | Deerfield Management Co | 8 months ago | 8135804 |
| 11. | Alkeon Capital Management, LLC | 8 months ago | 7093822 |
| 12. | Geode Capital Management, LLC | 8 months ago | 4837985 |
| 13. | Nuveen Asset Management, LLC | 8 months ago | 4814549 |
| 14. | RP Management, LLC | 8 months ago | 3846154 |
| 15. | Rock Springs Capital Management LP | 8 months ago | 3622358 |
| 16. | Fisher Asset Management, LLC | 8 months ago | 3338062 |
| 17. | GW&K Investment Management, LLC | 8 months ago | 3277600 |
| 18. | Caligan Partners LP | 8 months ago | 2583585 |
| 19. | Goldman Sachs Group Inc | 8 months ago | 2320529 |
| 20. | T. Rowe Price Associates, Inc. | 8 months ago | 2252749 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...